We are live on ! Find out more
JAMONY

Jacob Asset Management of New York Portfolio holdings

AUM $70.9M
1-Year Est. Return 14.28%
This Fund
S&P 500
This Quarter Est. Return
+5.03%
1 Year Est. Return
+14.28%
3 Year Est. Return
+22.72%
5 Year Est. Return
10 Year Est. Return
AUM
$303M
AUM Growth
+$44.8M
Cap. Flow
+$41.3M
Cap. Flow %
13.64%
Top 10 Hldgs %
38.16%
Holding
84
New
6
Increased
45
Reduced
8
Closed
2

Sector Composition

Rank Sector Weight
1 Technology 34.5%
2 Healthcare 23.4%
3 Communication Services 18.33%
4 Consumer Discretionary 7.01%
5 Financials 6.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
INBK icon
51
First Internet Bancorp
INBK
$255M
$1.41M 0.46%
45,378
-14,625
-24% -$496K
CTSO icon
52
Cytosorbents Corp
CTSO
$23.3M
$1.4M 0.46%
185,000
+60,000
+48% +$506K
ESPR
53
DELISTED
Esperion Therapeutics
ESPR
$1.36M 0.45%
64,434
MESO
54
Mesoblast
MESO
$2.18B
$1.31M 0.43%
87,700
+60,000
+217% +$942K
TRAK icon
55
ReposiTrak
TRAK
$152M
$1.26M 0.42%
228,958
+60,000
+36% +$341K
DMAC icon
56
DiaMedica Therapeutics
DMAC
$369M
$1.22M 0.4%
275,000
+90,000
+49% +$738K
AKUS
57
DELISTED
Akouos Inc
AKUS
$1.19M 0.39%
95,000
KRYS icon
58
Krystal Biotech
KRYS
$9.85B
$1.15M 0.38%
16,900
SLE icon
59
Super League Enterprise
SLE
$5.44M
$1.13M 0.37%
22
TLYS icon
60
Tilly's
TLYS
$121M
$1.13M 0.37%
70,800
RFL icon
61
Rafael Holdings
RFL
$103M
$1.09M 0.36%
21,598
-1,217
-5% -$53K
IDYA icon
62
IDEAYA Biosciences
IDYA
$3.56B
$1.08M 0.36%
51,700
-2,300
-4% -$47.2K
ATHX
63
DELISTED
Athersys, Inc. Common Stock
ATHX
$1.04M 0.34%
28,800
+5,600
+24% +$230K
ABUS icon
64
Arbutus Biopharma
ABUS
$907M
$1.03M 0.34%
340,000
+80,000
+31% +$248K
SCOR icon
65
Comscore
SCOR
$108M
$1M 0.33%
+10,000
New +$784K
BMTX
66
DELISTED
BM Technologies, Inc.
BMTX
$871K 0.29%
+70,000
New +$810K
APLS
67
DELISTED
Apellis Pharmaceuticals
APLS
$834K 0.28%
13,200
+3,200
+32% +$165K
DMTK
68
DELISTED
DermTech, Inc. Common Stock
DMTK
$831K 0.27%
+20,000
New +$822K
NAGE
69
Niagen Bioscience
NAGE
$242M
$828K 0.27%
84,000
+42,000
+100% +$366K
REED
70
DELISTED
Reeds, Inc. Common Stock
REED
$785K 0.26%
15,400
IIN
71
DELISTED
IntriCon Corporation
IIN
$719K 0.24%
32,000
WRN
72
Western Copper and Gold
WRN
$542M
$700K 0.23%
350,000
AEO icon
73
American Eagle Outfitters
AEO
$2.72B
$676K 0.22%
18,000
-9,000
-33% -$312K
HRTX icon
74
Heron Therapeutics
HRTX
$64.7M
$652K 0.22%
42,000
+20,000
+91% +$318K
XPL icon
75
Solitario Resources
XPL
$73.6M
$603K 0.2%
900,000
+360,000
+67% +$251K

Similar funds

Jacob Asset Management of New York's Q2 2021 Portfolio in Review

As of Q2 2021, Jacob Asset Management of New York held 84 positions worth $303M, up 17% from $258M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Jacob Asset Management of New York deployed $41.3M of net new capital in Q2 2021, opening 6 new positions and adding to 45 existing holdings. Its largest new stake was ContraFect Corporation: 5,125 shares worth $1.8M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 34% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was Esports Entertainment Group Inc. Common Stock, an estimated $942K trimmed.

  • Jacob Asset Management of New York's largest Q2 2021 buy was ContraFect Corporation: 5,125 shares worth $1.8M.
  • Jacob Asset Management of New York added most to Impinj in Q2 2021, an estimated $5.64M increase.
  • Jacob Asset Management of New York's biggest Q2 2021 reduction was Esports Entertainment Group Inc. Common Stock, cutting an estimated $942K.
  • Jacob Asset Management of New York fully exited CASTLIGHT HEALTH, INC. in Q2 2021, selling an estimated $978K.
  • Jacob Asset Management of New York's ten largest holdings make up 38% of its $303M portfolio in Q2 2021.
  • Jacob Asset Management of New York opened 6 new positions and closed 2 in Q2 2021.
  • Jacob Asset Management of New York's portfolio value rose 17% quarter-over-quarter to $303M.

Based on Jacob Asset Management of New York's 13F filing for Q2 2021, filed 4 Oct 2021.